ST诺泰收到注射用醋酸西曲瑞克、阿戈美拉汀片药品注册证书

Core Insights - ST诺泰 has received approval from the National Medical Products Administration for the drug registration certificates of injectable Acetate Cetrorelix and Agomelatine tablets [1] Group 1: Acetate Cetrorelix - Acetate Cetrorelix is a third-generation GnRH antagonist that offers unique clinical advantages in assisted reproductive technology compared to other similar drugs such as GnRH agonists or other antagonists like Ganirelix [1] - The drug demonstrates significantly faster onset, better safety (prevention of OHSS), shorter treatment cycles, and improved patient tolerance compared to GnRH agonists [1] - Compared to other antagonists like Ganirelix, Acetate Cetrorelix has milder injection reactions, making it an efficient and flexible choice in assisted reproduction [1] Group 2: Agomelatine - Agomelatine is a novel antidepressant with a unique and innovative dual action mechanism, distinguishing it from common antidepressants such as SSRIs (e.g., Sertraline, Fluoxetine) and SNRIs (e.g., Venlafaxine) [1] - It is the only antidepressant that can rapidly improve sleep without affecting daytime functioning, making it particularly valuable in the market for depression with insomnia [1] - The drug also has a very low risk of sexual dysfunction, minimal impact on weight, good tolerance, and fewer withdrawal reactions, securing an important position in the market for depression accompanied by insomnia [1]